Cargando…
MON-558 Radioiodine Is Not Associated with Quality of Life Outcomes in Early Stage Thyroid Cancer Survivors, a Matched-Pair Analysis.
Background: Radioiodine ablation (RAI) is often given as adjuvant therapy following thyroidectomy for differentiated thyroid cancer (DTC). The benefits of RAI are unclear in low-risk DTC, and the effects of RAI on health-related quality of life (HRQoL) are not well described. We hypothesized RAI wou...
Autores principales: | Chow, Kimberly, Helenowski, Irene, Goswami, Sneha, Yount, Susan, Sturgeon, Cord |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550947/ http://dx.doi.org/10.1210/js.2019-MON-558 |
Ejemplares similares
-
MON-LB76 Impact of Age on Survival and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Cancer Patients
por: Buffet, Camille
Publicado: (2020) -
MON-LB87 Recombinant Human TSH vs Thyroid Hormone Withdrawal Preparation for Radioiodine Ablation in Pediatric Differentiated Thyroid Cancer
por: Schumm, Max A, et al.
Publicado: (2020) -
MON-443 SPECT/CT Localization of Incidental Diverticular Bleed After Radioiodine (i(131)) Therapy for Metastatic Thyroid Cancer
por: Doshi, Sejal B, et al.
Publicado: (2020) -
SUN-558 Methimazole Treatment of Thyrotoxicosis in the Setting of Ischemic Hepatitis
por: Chokshi, Sheel, et al.
Publicado: (2019) -
SAT558 Papillary Thyroid Carcinoma With Anaplastic Transformation in a Filipino Male Treated With Radioactive Iodine and Radiotherapy: A Case Report
por: Apa-Ap, Archimedes Almasol, et al.
Publicado: (2023)